Proteomics International Laboratories Ltd (ASX: PIQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Proteomics International Laboratories Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $109.47 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 105.26 million
Earnings per share -0.027
Dividend per share N/A
Year To Date Return 35.22%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Proteomics International Laboratories Ltd (ASX: PIQ)
Latest News

PIQ ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial scale study of the structure and function of proteins. Its operations are divided into PromarkerD that targets the global diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

PIQ Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 Sep 2021 $1.04 $-0.01 -0.95% 17,046 $1.06 $1.07 $1.04
15 Sep 2021 $1.06 $-0.02 -1.86% 124,991 $1.06 $1.07 $0.99
14 Sep 2021 $1.08 $0.00 0.00% 41,769 $1.09 $1.09 $1.05
13 Sep 2021 $1.08 $-0.04 -3.60% 6,335 $1.08 $1.08 $1.08
10 Sep 2021 $1.11 $-0.02 -1.77% 4,330 $1.11 $1.11 $1.11
09 Sep 2021 $1.13 $0.02 1.80% 49,900 $1.11 $1.13 $1.07
08 Sep 2021 $1.11 $-0.01 -0.89% 31,941 $1.14 $1.14 $1.11
07 Sep 2021 $1.13 $0.01 0.90% 20,762 $1.11 $1.13 $1.11
06 Sep 2021 $1.11 $-0.05 -4.31% 33,117 $1.17 $1.17 $1.11
03 Sep 2021 $1.16 $0.02 1.76% 77,736 $1.13 $1.16 $1.12
02 Sep 2021 $1.14 $0.08 7.58% 37,252 $1.11 $1.17 $1.10
01 Sep 2021 $1.06 $-0.05 -4.55% 58,659 $1.10 $1.12 $1.06
31 Aug 2021 $1.10 $0.00 0.00% 200,882 $1.10 $1.12 $1.08
30 Aug 2021 $1.10 $0.05 4.74% 27,004 $1.05 $1.10 $1.05
27 Aug 2021 $1.06 $-0.01 -0.94% 38,696 $1.07 $1.07 $1.03
26 Aug 2021 $1.07 $0.01 0.95% 600 $1.07 $1.07 $1.07
25 Aug 2021 $1.06 $-0.01 -0.94% 21,772 $1.07 $1.07 $1.06
24 Aug 2021 $1.06 $0.01 0.95% 16,465 $1.06 $1.06 $1.06
20 Aug 2021 $1.05 $0.01 0.96% 166,178 $1.05 $1.06 $1.04
19 Aug 2021 $1.04 $-0.02 -1.89% 86,108 $1.06 $1.06 $1.04
18 Aug 2021 $1.06 $0.00 0.00% 19,780 $1.07 $1.09 $1.06

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
24 Sep 2020 Richard Lipscombe Transfer 710 $344,350
Off-market transfer.
24 Sep 2020 Richard Lipscombe Transfer 710 $344,350
Off-market transfer.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Terry Sweet Non-Executive ChairmanNon-Executive Director Jun 2014
Mr Sweet has been a Director of several listed companies over the past 30 years in both executive and non-executive capacities. These companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, Heartlink Ltd, and Scientific Services Ltd. His interest now lie in the area of development and supervision of a culture of Board integrity, commensurate with technology commercialisation.
Mr Paul Edward House Non-Executive Director Nov 2017
Mr House has over 25 years' experience with multi-national corporations. He recently served eight years as the Managing Director of SGS India. Previously held CFO and COO roles and has a record for delivery of business performance targets, revenue growth, margin improvement, market share and productivity, across multiple services, markets and borders.
Dr Richard Lipscombe Managing Director Jun 2014
Dr Lipscombe is practised business manager and protein chemist expert in analysing biomolecules using proteomics techniques. He has an experience in chemistry, immunology, mass spectrometry, peptide synthesis, performance computing and robotics. Richard has international experience in both science and business over a 30-year period in Australia, USA and the UK, including work in hospital and academic laboratories and commercial organisations. After managing the Protein Analysis Facility at the University of Western Australia, he co-founded Proteomics International Pty Ltd in 2001.
Mr Ian Roger Moore Non-Executive Director Oct 2016
Mr Moore has 40 years' experience in the international pharmaceutical industry, including almost 30 years as President of Novo Nordisk Japan. Roger established Novo's organisation in Japan and worked for the company until his retirement as Chairman at the end of 2007. From 2000, Roger was appointed Senior Vice President, Japan and Oceania Region, responsible for Novo Nordisk's business in Japan, Australia, New Zealand and the Pacific. He was also appointed a member of the Senior Management Board, Novo Nordisk A/S.
Ms Karen Logan Company Secretary
-
Javed Khan Business Manager - Analytical Services
-
Pearl Tan Business Manager - PromarkerD
-
Karen Logan Company Secretary
-
Kerryn Garrett General Manager
-
John C. Morrison Head of Business Development
-
Scott Bringans Research Manager
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Richard Lipscombe 18,058,704 19.54%
John Sutherland Richardson Dunlop 3,855,188 4.17%
Xylo Pty Ltd 3,003,700 3.25%
Sparrow Holdings Pty Ltd 2,335,500 2.53%
J P Morgan Nominees Australia Pty Limited 2,011,426 2.18%
Randolph Resources Pty Limited 1,949,000 2.11%
Littlejohn Embrey Engineering Pty Ltd 1,535,500 1.66%
Slade Technologies Pty Ltd 1,364,500 1.48%
Scintilla Strategic Investments Limited 1,122,400 1.21%
Lisa Floan 1,100,000 1.19%
Bjouxz Pty Ltd 990,000 1.07%
Konrad Floan 887,000 0.96%
Saint Smsf Pty Ltd 814,717 0.88%
Altor Capital Management Pty Ltd 810,000 0.88%
Bfm Superannuation Fund Pty Ltd 800,000 0.87%
Himstedt & Co Pty Ltd 768,442 0.83%
Moore & Sotomi Investments Pty Ltd 717,000 0.78%
Patricia Marton 686,037 0.74%
Camberwell Gynaecology Clinic Pty Ltd 649,400 0.70%
Darlene Valerie Gould 647,404 0.70%

Profile

since

Note